SCHEMBL1259613

SCHEMBL1259613

NC(=O)NN1CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL244127 0.94
SCHEMBL7747487 0.92 HTT (0.45)
Hydrochloric Acid SCHEMBL27321583 0.92 HTT (0.41)
SCHEMBL1259794 0.92 HTT (0.45)
SCHEMBL7749230 0.92 HTT (0.45)
SCHEMBL15282042 0.92 HTT (0.45)
SCHEMBL7749096 0.92 HTT (0.45)
Hydrochloric Acid SCHEMBL27317890 0.90 HTT (0.44)
Hydrochloric Acid SCHEMBL27543811 0.90 HTT (0.44)
SCHEMBL337968 0.88

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114181196-A Compound for inhibiting and degrading PARP enzyme, preparation method and pharmaceutical application thereof 海思科医药集团股份有限公司 2022-03-15 CN claimed
CN-101684084-A Tetracycline compounds containing carbamido SHANDONG XUANZHU MEDICINE TECH 2010-03-31 CN claimed
CN-114349748-A Indazole derivative, preparation method and medical application thereof 四川海思科制药有限公司 2022-04-15 CN disclosed
CN-114181196-A Compound for inhibiting and degrading PARP enzyme, preparation method and pharmaceutical application thereof 海思科医药集团股份有限公司 2022-03-15 CN disclosed
US-11173144-B2 Adrenergic receptor modulating compounds and methods of using the same THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2021-11-16 US disclosed
US-20200237724-A1 ADRENERGIC RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2020-07-30 US disclosed
CN-110072857-A 1, 3-disubstituted cyclobutanone or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2019-07-30 CN disclosed
EP-3454845-A1 ADRENERGIC RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME The Board of Trustees of the Leland Stanford Junior University (US) 2019-03-20 EP disclosed
WO-2017197324-A1 ADRENERGIC RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2017-11-16 WO disclosed
US-8445509-B2 Fused heterocyclic derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-21 US disclosed
WO-2012172093-A1 DIHYDROINDOLIZINE DERIVATE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS MERZ PHARMA GMBH & CO. KGAA (DE) 2012-12-20 WO disclosed
EP-2162445-A1 HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2010-03-17 EP disclosed
WO-2009136663-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-12 WO disclosed
US-20090163488-A1 FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed
WO-2009073788-A1 COMPOSITIONS AND METHODS FOR TREATING MENOPAUSAL FEMALES FIRESTONE LEIGH H (US) 2009-06-11 WO disclosed
US-7514562-B2 Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain GLAXO GROUP LIMITED (GB) 2009-04-07 US disclosed
WO-2008150015-A1 HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-11 WO disclosed
US-20060276447-A1 Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain GLAXO GROUP LIMITED (GB) 2006-12-07 US disclosed
EP-1601665-A2 UREA DERIVATIVES GLAXO GROUP LIMITED (GB) 2005-12-07 EP disclosed
WO-2004078744-A2 UREA DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR ANTAGONISTS IN THE TREATMENT OF PAIN GLAXO GROUP LIMITED (GB) 2004-09-16 WO disclosed